HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity

Title
HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity
Authors
Keywords
-
Journal
MOLECULAR CANCER RESEARCH
Volume -, Issue -, Pages molcanres.1109.2018
Publisher
American Association for Cancer Research (AACR)
Online
2019-05-15
DOI
10.1158/1541-7786.mcr-18-1109

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More